全文获取类型
收费全文 | 1002644篇 |
免费 | 77243篇 |
国内免费 | 2614篇 |
专业分类
耳鼻咽喉 | 13006篇 |
儿科学 | 34657篇 |
妇产科学 | 28664篇 |
基础医学 | 146051篇 |
口腔科学 | 28080篇 |
临床医学 | 90989篇 |
内科学 | 194678篇 |
皮肤病学 | 22979篇 |
神经病学 | 79759篇 |
特种医学 | 38671篇 |
外国民族医学 | 305篇 |
外科学 | 150514篇 |
综合类 | 24039篇 |
一般理论 | 396篇 |
预防医学 | 78548篇 |
眼科学 | 22743篇 |
药学 | 72217篇 |
3篇 | |
中国医学 | 2032篇 |
肿瘤学 | 54170篇 |
出版年
2018年 | 10661篇 |
2017年 | 8326篇 |
2016年 | 9461篇 |
2015年 | 10708篇 |
2014年 | 14567篇 |
2013年 | 22257篇 |
2012年 | 29342篇 |
2011年 | 31208篇 |
2010年 | 18689篇 |
2009年 | 17611篇 |
2008年 | 29100篇 |
2007年 | 30821篇 |
2006年 | 31310篇 |
2005年 | 29969篇 |
2004年 | 29249篇 |
2003年 | 28088篇 |
2002年 | 27116篇 |
2001年 | 47143篇 |
2000年 | 48259篇 |
1999年 | 40477篇 |
1998年 | 11253篇 |
1997年 | 10165篇 |
1996年 | 10213篇 |
1995年 | 9831篇 |
1994年 | 9150篇 |
1993年 | 8534篇 |
1992年 | 32417篇 |
1991年 | 31638篇 |
1990年 | 31196篇 |
1989年 | 30024篇 |
1988年 | 27320篇 |
1987年 | 27480篇 |
1986年 | 25586篇 |
1985年 | 24744篇 |
1984年 | 18468篇 |
1983年 | 15592篇 |
1982年 | 9343篇 |
1981年 | 8425篇 |
1979年 | 16930篇 |
1978年 | 12282篇 |
1977年 | 10357篇 |
1976年 | 9794篇 |
1975年 | 10218篇 |
1974年 | 12363篇 |
1973年 | 11884篇 |
1972年 | 10930篇 |
1971年 | 10166篇 |
1970年 | 9416篇 |
1969年 | 8760篇 |
1968年 | 8138篇 |
排序方式: 共有10000条查询结果,搜索用时 750 毫秒
171.
172.
Prolidase deficiency is a rare autosomal recessive disorder characterized by cutaneous ulcers, facial dysmorphism, recurrent infections, and intellectual disability. We report a unique case of a 6‐year‐old boy with prolidase deficiency and Crohn's disease who presented with lower extremity ulcers. Cutaneous ulcers due to prolidase deficiency are historically resistant to treatment, and we report success with the novel use of topical tacrolimus. 相似文献
173.
J.J. Crowley R.B. Warren J.C. Cather 《Journal of the European Academy of Dermatology and Venereology》2019,33(9):1676-1684
Psoriasis is a chronic disease that requires long‐term treatment. Consequently, understanding the safety and tolerability of any potential treatment over time is critical to effective prescribing. The biologic agents currently available for the treatment of psoriasis target a number of different inflammatory cytokines involved in psoriasis disease pathogenesis. The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (IL)‐23. This article reviews published data on the safety of these IL‐23p19 inhibitors in patients with psoriasis compared with other currently available biologic therapies. Data from randomized, placebo‐ and active‐controlled phase 3 clinical trials show tildrakizumab, guselkumab and risankizumab to have a favourable risk–benefit profile in patients with moderate to severe psoriasis. No significant safety concerns have been observed for any of these IL‐23p19 inhibitors in the data published to date. The most commonly reported adverse events (AEs) associated with these agents in phase 3 studies were upper respiratory tract infections. No increase was seen in rates of serious infections, malignancies or major adverse cardiovascular events, with no signals suggestive of an elevated risk of opportunistic infections, active tuberculosis or reactivation of latent tuberculosis infection, mucocutaneous Candida infections, triggering or worsening of inflammatory bowel disease, demyelinating disorders or suicidal ideation. Selectively targeting IL‐23p19 may help avoid AEs that have been associated with biologic agents with other mechanisms of action. Data from long‐term extension studies and patient registries will further establish the safety profile of IL‐23p19 inhibitors for the treatment of moderate to severe psoriasis in routine practice. 相似文献
174.
175.
Umar Nadia K. Badshah Maaz B. Sandrasegaran Kumar Ghabril Marwan Agarwal Saurabh Tann Mark Lacerda Marco Kwo Paul Y. 《Digestive diseases and sciences》2015,60(7):2196-2200
Digestive Diseases and Sciences - To determine whether the presence of portal vein thrombosis (PVT) where venous flow within the liver may be altered may delay the diagnosis of HCC and be... 相似文献
176.
ABSTRACTAlthough exclusive breastfeeding has been linked to lower rates of postnatal HIV transmission compared to nonexclusive breastfeeding, mechanisms underlying this are unclear. Across a longitudinally sampled cohort of South African infants, we showed that exclusively breastfed (EBF) infants had altered gut bacterial communities when compared to nonexclusively breastfed (NEBF) infants, as well as reduced peripheral CD4 + T cell activation and lowered chemokine and chemokine receptor expression in the oral mucosa. We further demonstrated that the relative abundance of key taxa was correlated with peripheral CD4 + T cell activation. Here, we supplement those findings by using compositional data analyses to identify shifts in the abundance of several Bifidobacteria strains relative to select strains of Escherichia, Bacteroides, and others that are associated with the transition to NEBF. We illustrate that the abundance ratio of these taxa is tightly correlated with feeding modality and is a strong predictor of peripheral T cell activation. More broadly, we discuss our study in the context of novel developments and explore future directions for the field. 相似文献
177.
178.
179.
Letter: faecal volatile organic metabolites,promising biomarkers in inflammatory bowel disease and Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Authors’ reply 下载免费PDF全文
I. Ahmed R. Greenwood B. Costello N. Ratcliffe C. Probert 《Alimentary pharmacology & therapeutics》2016,43(11):1241-1242
180.